Business
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts.
About this update from Regenxbio Inc.
ROCKVILLE, Md. , May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts. Oral Presentations: The oral presentations include an overview of recent advancements in production titer and product quality achieved through REGENXBIO's NAVXpress ® manufacturing platform and an encore presentation of topline pivotal data from RGX-202, the company's next generation gene therapy program for Duchenne muscular dystrophy. Title: Advancing AAV manufacturability toolbox for early programs and beyond Presenter: Metewo Selase Kosi Enuameh , Ph.D ., Associate Director, Vector Core at REGENXBIO Presentation: 266 Session: AAV Critical Quality Attributes Date/Time: Thursday, May 14, 8:45 – 9:00am ET Location: MCEC Room 204AB (Level 2) Title: RGX-202: Investigational gene therapy for Duchenne Muscular Dystrophy Presenter: Aravindhan Veerapandiyan, M.D., Director of the Comprehensive Neuromuscular Program, PPMD Certified Duchenne Care Center, and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's Hospital Presentation: 506 Session: In vivo clinical trials in eye and muscle disorders Date/Time: Friday, May 15, 4:30 – 4:45pm ET Location: MCEC Room 210ABC (Level 2) Poster Presentations: These presentations demonstrate REGENXBIO's continued leadership in the discovery and advancement of next-generation gene therapies for rare and retinal diseases, and highlight the company's unique capsid engineering and translational capabilities. Title: NVG82, a capsid engineered for enhanced outer retinal gene transfer when administered in the suprachoroidal space, demonstrates superior on-target activity compared to AAV8 Poster: 1031 Presenter: Brendan Lilley , Ph.D ., Director of Ophthalmology Research, REGENXBIO Location: MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit level) Date/Time: Tuesday, May 12, 5:00 – 6:30pm ET Title: Examination of Route-Dependent Ocular Transduction in Rodent Models by the Novel AAV Capsid NVG82 Poster: 3031 Presenter: Huzzatul Mursalin , Ph.D ., Scientist II, Gene Therapy Research, REGENXBIO Location: MCEC Exhibit and Poster Hall (Hall B2-C, Exhibit level) Date/Time: Thursday, May 14, 5:00 – 6:30pm ET Title: Development of an engineered hybrid AAV with reduced liver and DRG transduction and high productivity Poster: 3030 Presenter: Samantha Yost , Ph.D ., Senior Scientist, Gene Therapy Research, REGENXBIO Location: MCEC Exhibit and Poster Hall (Hall B2-C, Exhibit level) Date/Time: Thursday, May 14, 5:00 – 6:30pm ET Title: Single-nuclei transcriptomic analysis of skeletal muscle mRNA in mdx mice treated with RGX-202, an AAV vector encoding micro-dystrophin Poster: 3499 Presenter: Justin Glenn, Ph.D., Principal Scientist, Gene Therapy Research, REGENXBIO Location: MCEC Exhibit and Poster Hall (Hall B2-C, Exhibit level) Date/Time: Thursday, May 14, 5:00 – 6:30pm ET All presentations will be available on the Publications page of REGENXBIO's website, www.regenxbio.com . ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie . Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM . Contacts: Dana Cormack Corporate Communications [email protected] Investors: George E. MacDougall Investor Relations [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene--cell-therapy-2026-annual-meeting-302765129.html